ABSTRACTS OF THE 21st ANNUAL MEETING OF THE ITALIAN ...

(145 Gy) in 380 patients and as a boost (100 Gy) in
association with external beam radiotherapy (45-50.4 Gy) in
29 patients. A short course of hormonal therapy was
performed pre-BT in 153 patients. The median age was 66
years (49-78); the NCCN risk class was low, medium and
high in 68%, 30% and 2% of the patients, respectively. CTbased
dosimetry at four weeks was used for post-planning
evaluation. D90 and V100 were recorded for each patient,
along with other dosimetric and clinical parameters.
Biochemical relapse was defined according to Phoenix
ASTRO Consensus Conference (nadir +2 ng/ml). From
March 2005, QL was prospectively assessed by a self-filled
QL validated questionnaire in a consecutive series of 228
patients. Results: A D90≥100% of prescribed dose and a
V100 ≥90% of prostate volume were achieved in 83% of
patients. After a median follow-up of 55 months, 36 patients
developed biochemical relapse, with a clinical component in
8 patients. The 5- and 10-year relapse-free survival (RFS) was
92% and 79%, respectively. At this time, 30 patients had died
(27 relapse-free), with a 5- and 10-year overall survival of
93% and 85%, respectively. The 5- and 10-year RFS in lowrisk
cancer was 95% and 80% vs. 88% and 73% in
intermediate-high risk (p: NS). Patients with better dosimetric
parameters (V100≥90% and D90≥100%) had a better RFS (5and
10-year: 95% and 82% vs. 80% and 62%; p